In Vitro Evidences of Heparin’s Effects on Embryo Implantation and Trophoblast Development


Heparin seems to be effective in ameliorating pregnancy outcome in thrombophilic women with previous recurrent pregnancy loss, preeclampsia, intrauterine growth restriction and sudden fetal death. A prophylactic effect of heparin treatment has also been proposed in terms of prevention of adverse pregnancy outcomes recurrence in women with history of recurrent miscarriage, severe preeclampsia, placental abruption, low neonatal birth weight and intrauterine fetal death not related to thrombophilia, although literature in this field is quite controversial.

The molecular mechanisms by which heparin might exert its potential therapeutic effects in human reproduction are still not fully understood. In this article we review the current knowledge in this research field, focusing on in vitro evidences of heparin’s mechanisms of action in the processes of embryo implantation and trophoblast invasion.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 510

This is the net price. Taxes to be calculated in checkout.


  1. 1.

    Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol. 2005; 128(5):593–601.

  2. 2.

    Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003; 12(7):524–529.

  3. 3.

    Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005; 18(2):CD002859.

  4. 4.

    Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000; 83(5):693–697.

  5. 5.

    Brenner B. Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. Blood. 2003; 102(11):43A.

  6. 6.

    Gris JC, Mercier E, Quere I, et al. Low molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004; 103(10):3695–3699.

  7. 7.

    Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003; 1(3):33–438.

  8. 8.

    Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001; 20(1):35–44.

  9. 9.

    Grandone E, Brancaccio V, Colaizzo BS, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril. 2002; 78(2):371–375.

  10. 10.

    Leduc L, Dubois E, Takser L, et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007; 29(10):787–793.

  11. 11.

    Paidas M, Ku DH, Triche E, Lockwood C, Arkel Y. Does heparin therapy improve pregnancy outcome in patients with thrombophilias? J Thromb Haemost. 2004; 2(7):1194–1195.

  12. 12.

    Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7(1):58–64.

  13. 13.

    Kupferminc M, Rimon E, Many A, Maslovitz S, Lessing JB, Gamzu R. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis. 2011; 22(2):123–126.

  14. 14.

    Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005; 45(1):86–91.

  15. 15.

    Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362(17):1586–1596.

  16. 16.

    Greer IA. Antithrombotic therapy for recurrent miscarriage? N Engl J Med. 2010; 362(17):1630–1631.

  17. 17.

    Clark P, Walker ID, Langhorne P, et al; Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115(21):4162–4167.

  18. 18.

    Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey AA, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008; 278(1):33–38.

  19. 19.

    Smith GC, Smith MF, McNay MB, Fleming JE. First-trimester growth and the risk of low birth weight. N Engl J Med. 1998; 339(25):1817–1822.

  20. 20.

    Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early-pregnancy origins of low birth weight. Nature. 2002; 417(6892):916.

  21. 21.

    Genbacev OD, Prakobphol A, Foulk RA, et al. Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science. 2003; 299(5605):405–408.

  22. 22.

    Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 1992; 258(5084):964–969.

  23. 23.

    McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997; 100(11 suppl):S97–S103.

  24. 24.

    Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004; 22: 129–156.

  25. 25.

    Rosen SD. Homing in on L-selectin. J Immunol. 2006; 177(1):3–4.

  26. 26.

    Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins—correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005; 11(19 pt 1):7003–7011.

  27. 27.

    Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4(2):118–132.

  28. 28.

    Xue WC, Feng HC, Tsao SW, et al. Methylation status and expression of E-cadherin and cadherin-11 in gestational trophoblastic diseases. Int J Gynecol Cancer. 2003; 13(6):879–888.

  29. 29.

    Li HW, Cheung AN, Tsao SW, Cheung AL, O WS. Expression of e-cadherin and beta-catenin in trophoblastic tissue in normal and pathological pregnancies. Int J Gynecol Pathol. 2003;22(1):63–70.

  30. 30.

    Shih IeM, Hsu MY, Oldt RJ 3rd, Herlyn M, Gearhart JD, Kurman RJ. The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta. 2002; 23(10):706–715.

  31. 31.

    Erden O, Imir A, Guvenal T, et al. Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry. Hum Reprod. 2006; 21(11):3014–3018.

  32. 32.

    Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince G. Effects of low molecular weight and unfractionated heparin on trophoblast function. Obstet Gynecol. 2004; 104(2):354–361.

  33. 33.

    Benirschke K, Kaufmann P, Baergen RN. Pathology of the Human Placenta. New York, NY: Springer; 2006.

  34. 34.

    Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynecol. 1986; 93(10):1049–1049.

  35. 35.

    Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004; 11(6):342–352.

  36. 36.

    Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaga-nathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod. 2007; 22(9):2523–2527.

  37. 37.

    Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007; 28(4):298–304.

  38. 38.

    Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1:177–191.

  39. 39.

    Di Federico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotropho-blasts within the uterine wall. Am J Pathol. 1999; 155(1):293–301.

  40. 40.

    Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA. Placental apoptosis in preeclampsia. Obstet Gynecol. 2000; 96(2):271–276.

  41. 41.

    Naicker T, Khedun SM, Moodley J, Pijnenborg R. Quantitative analysis of trophoblast invasion in preeclampsia. Acta Obstet Gynecol Scand. 2003; 82(8):722–729.

  42. 42.

    Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol. 2002; 187(5):1416–1423.

  43. 43.

    Leach RE, Khalifa R, Ramirez ND, et al. Multiple roles for heparin-binding epidermal growth factor-like growth factor are suggested by its cell-specific expression during the human endometrial cycle and early placentation. J Clin Endocrinol Metab. 1999; 84(9):3355–3363.

  44. 44.

    Raab G, Klagsbrun M. Heparin binding EGF growth factor. Effects of aPL on trophoblasts via inhibition of HB-EGF expression. Biochim Biophys Acta. 1997; 1333(3):179–199.

  45. 45.

    Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4 + and CD8 + T cells. Proc Natl Acad Sci USA. 1994; 91(8):2890–2894.

  46. 46.

    Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 2000; 11(4):335–344.

  47. 47.

    Ongusaha PP, Kwak JC, Zwible AJ, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004; 64(15):5283–5290.

  48. 48.

    Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308(5728):1592–1594.

  49. 49.

    Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. Heparin-binding EGF-like growth factor regulates human extra-villous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol. 2004; 266(2):223–237.

  50. 50.

    Thompson SA, Higashiyama S, Wood K, et al. Characterization of sequences within heparinbinding EGF-like growth factor that mediate interaction with heparin. J Biol Chem. 1994; 269(4):2541–2549.

  51. 51.

    Di Simone N, Marana R, Castellani R, et al. Decreased expression of Heparin-binding epidermal growth factor–like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum. 2010; 62(5):1504–1512.

  52. 52.

    Isaka K, Usuda S, Ito H, et al. Expression and activation of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta. 2003; 24(1):53–64.

  53. 53.

    Librach CL, Werb Z, Fitzgerald ML, et al. 92-kDa type IV col-lagenase mediates invasion of human cytotrophoblasts. J Cell Biol. 1991; 113(2):437–449.

  54. 54.

    Straszewski-Chavez SL, Abrahams VM, Mor G. The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev. 2005; 26(7):877–897.

  55. 55.

    Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol. 1997; 177(6):1395–1401.

  56. 56.

    Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001; 184(6):1249–1250.

  57. 57.

    Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotropho-blast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 2002; 186(1):158–166.

  58. 58.

    Choi HK, Choi BC, Lee SH, Kim JW, Cha KY, Baek KH. Expression of angiogenesis-and apoptosis-related genes in chorionic villi derived from recurrent pregnancy loss patients. Mol Reprod Dev. 2003; 66(1):24–31.

  59. 59.

    Hills FA, Abrahams VM, González-Timón B, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006; 12(4):237–243.

  60. 60.

    Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion-and death receptor-controlled pathways. Proc Natl Acad Sci U S A. 2002; 99(22):14386–14391.

  61. 61.

    Ishikawa Y, Kitamura M. Inhibition of glomerular cell apoptosis by heparin. Kidney Int. 1999; 56(3):954–963.

  62. 62.

    Bose P, Black S, Kadyrov M, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004; 191(6):2125–2131.

  63. 63.

    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295–306.

  64. 64.

    Woodhams BJ, Candotti G, Shaw R, Kernoff PB. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res. 1989; 55(1):99–107.

  65. 65.

    Chamley LW. Action of anticardiolipin andantibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 1998; 352(9133):1037–1038.

  66. 66.

    Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol. 2003; 101(3):455–462.

  67. 67.

    Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991; 41(3):179–186.

  68. 68.

    Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002; 17(4):1067–1071.

  69. 69.

    Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol. 1992; 22(1):1–14.

  70. 70.

    Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci U S A. 1993; 90(14):6464–6467.

  71. 71.

    Di Simone N, Meroni PL, Del Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta-2-glycoprotein I. Arthritis Rheum. 2000; 43(1):140–150.

  72. 72.

    Ornoy A, Yacobi S, Matalon ST, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003; 12(7):573–578.

  73. 73.

    Di Simone N, Ferrazzani S, Castellani R, et al. Heparin and low dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod. 1997; 12(9):2061–2065.

  74. 74.

    Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod. 1999; 14(2):489–495.

  75. 75.

    Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis SA. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem. 2002; 277(4):2644–2649.

  76. 76.

    Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999; 81(1):87–95.

  77. 77.

    Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin In vest. 2003; 112(11):1644–1654.

  78. 78.

    Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11):1222–1226.

  79. 79.

    Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effect of heparin and N-acetyl heparin on ischemia/ reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res. 1994; 75(4):701–710.

  80. 80.

    Koenig A, Norgard-Sumnicht K, Lindhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosa-minoglycans with the selectins. Implications for the use of unfrac-tionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998; 101(4):877–889.

  81. 81.

    Wang L, Brown JR, Varki A, Esko JD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest. 2002;110(1):127–136.

  82. 82.

    Rops AL, van der Vlag J, Jacobs CW, et al. Heparan sulphate proteoglycans in glomerular inflammation. Kidney Int. 2004; 65(3):768–785.

  83. 83.

    Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002; 100(5):1869–1877.

  84. 84.

    Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006; 133(1):62–67.

  85. 85.

    Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174(1):485–490.

Download references

Author information

Correspondence to Nicoletta Di Simone MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tersigni, C., Marana, R., Santamarìa, A. et al. In Vitro Evidences of Heparin’s Effects on Embryo Implantation and Trophoblast Development. Reprod. Sci. 19, 454–462 (2012).

Download citation


  • heparin
  • in vitro
  • trophoblast invasion